ACCESS TO ADVANCED HEALTH INSTITUTE
Doing business as AAHI
SEATTLE, WA, 98109
Prime contracting experience
6 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | — | $10,833,357 | Sep 16, 2026 | Sep 21, 2018 – Aug 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | — | $13,771,809 | Aug 31, 2026 | Sep 9, 2019 – Apr 25, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES | — | $5,018,496 | Jun 26, 2025 | Jul 5, 2023 – Jun 26, 2025 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | INFECTIOUS DISEASE RESEARCH INSTITUTE: R&D OF INTRANASAL ADMINISTRATION OF RNA VACCINES AGAINST RESPIRATORY PATHOGENS | — | $748,885 | Oct 12, 2023 | Sep 20, 2021 – Mar 31, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | — | $11,492,655 | Mar 29, 2023 | Jul 23, 2014 – Aug 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | INVESTIGATIONAL PRODUCTS GLA-SE ADJUVANT FORMULATION AND LYOPHILIZED ID93 FROM IDRI FOR DAIDS-FUNDED CLINICAL TRIALS | — | $780,764 | Feb 28, 2022 | Sep 3, 2021 – Apr 30, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | PRODUCTION OF HIV-1 ENV TRIMER - CONJUGATED LIPOSOMES A10348 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: NY Parent award description: THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF View parent award on USAspending | HHSN272201600011IUSAspending | $569,055 | Mar 3, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.